Breaking News Instant updates and real-time market news.

PCRX

Pacira

$33.30

3.8 (12.88%)

, HRTX

Heron Therapeutics

$26.75

-1.15 (-4.12%)

06:05
04/09/18
04/09
06:05
04/09/18
06:05

Piper reiterates Overweight on Pacira after 'watershed' nerve block approval

FDA approval of Pacira Pharmaceuticals' (PCRX) Exparel as a brachial plexus block "is something of a watershed" in that the agency has never before approved any local or regional anesthetic for a single, specific setting, Piper Jaffray analyst David Amsellem tells investors in a research note. He believes the approval suggests an increasingly aggressive FDA approach towards the opioid crisis. Amsellem points out, however, that feedback from his surgeon survey suggests a "strong degree of enthusiasm" for Heron Therapeutics' (HTRX) HTX-011. However, the feedback also indicates that non-opioid, post-operative pain space is not a zero-sum game, the analyst writes. He believes Exparel can grow "even amid greater competition." Amsellem reiterates an Overweight rating on Pacira with a $44 price target.

PCRX

Pacira

$33.30

3.8 (12.88%)

HRTX

Heron Therapeutics

$26.75

-1.15 (-4.12%)

  • 16

    Apr

  • 08

    May

PCRX Pacira
$33.30

3.8 (12.88%)

03/19/18
JEFF
03/19/18
NO CHANGE
Target $30
JEFF
Buy
Heron pain drug 'hits a home run' in Phase III studies, says Jefferies
Jefferies analyst Biren Amin says Heron Therapeutics's (HRTX) HTX-011 "hits a home run" by meeting all primary and key secondary endpoints this morning from Phase III trials in bunionectomy and hernia repair. Safety looked clean in both studies, and HTX-011 produced durable pain reduction up to 72 hours and significant opioid sparing effect and differentiates from generic bupivacaine, Amin tells investors in a research note. The analyst believes HTX-011 should receive a superiority claim versus generic bupivacaine in its label for both bunionectomy and hernia surgery. Amin notes that Pacira's (PCRX) Exparel does not have this claim in its label. He assumes peak sales of $545M for HTX-011 and keeps a Buy rating on Heron with $30 price target.
03/20/18
GHSC
03/20/18
NO CHANGE
Target $42
GHSC
Buy
Pacira price target lowered to $42 after Heron data at Seaport Global
Seaport Global analyst Corey Davis noted that Heron Therapeutics (HRTX) reported positive results from its two Phase 3 studies of HTX-011 for postoperative pain in bunionectomy and herniorrhaphy. While Heron's HTX-011 data suggest some competition in 2020 for Pacira's (PCRX) Exparel, Davis said dose and volume "present problems" and that Heron "may run into a pricing problem" as well. He reiterates his Buy rating on Pacira shares, though he lowered his price target on the stock to $42 from $50, noting that he has formally removed nerve block revenue for Exparel entirely from his model after the negative FDA AdCom last month.
03/21/18
JEFF
03/21/18
NO CHANGE
Target $49
JEFF
Buy
Pacira shares could be positioned for rebound, says Jefferies
Jefferies analyst David Steinberg believes shares of Pacira Pharmaceuticals could be positioned for a rebound after Symphony Health data indicated Exparel posted "well above trend growth" in February. Sales were $24M, up 3.4% from last month and up 12.6% year-over-year, according to Symphony. The data have shown double digit year-over-years gains in four of the past five months, versus just one of nine months prior, Steinberg tells investors in a research note. He believes Pacira is attractively valued at current levels and keeps a Buy rating on the shares with a $49 price target.
04/06/18
WEDB
04/06/18
NO CHANGE
Target $72
WEDB
Outperform
Wedbush says FDA response for Pacira's EXPAREL in nerve block due
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $72 price target on Pacira Pharmaeuticals ahead of the expected PDUFA date for potential expansion of EXPAREL's label to specify nerve block. In a research note to investors, the analyst said she is "hopeful" that EXPAREL could potentially be used to provide improved outcomes in long-acting regional analgesia compared to infusion pumps or opioids. Whether required post-approval or in preparation for future regulatory review, she sees Pacira to continuing to evaluate EXPAREL in different nerve block techniques.
HRTX Heron Therapeutics
$26.75

-1.15 (-4.12%)

03/20/18
NEED
03/20/18
NO CHANGE
Target $42
NEED
Buy
Heron Therapeutics price target raised to $42 from $30 at Needham
Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $42 after the company's phase 3 trial results for HTX-011 on post-surgical pain management. The analyst says the treatment met all the primary and secondary endpoints while also demonstrating superiority over placebo and bupivacaine in terms of pain relief and opioid consumption. Belanger keeps his Buy rating on Heron Therapeutics, adding that the HTX-011 could be "game changer", with NDA filing coming in the second half of this year.
04/05/18
LSCM
04/05/18
NO CHANGE
Target $42
LSCM
Buy
Heron 'ready for liftoff' after secondary offering, says Lake Street
Lake Street analyst Bruce Jackson updated his model for Heron Therapeutics following the recently completed stock offering. In a research note partially titled, "Fuel Tank Filled, Ready For Lift Off," the analyst reiterates a Buy rating on Heron with a $42 price target. New Phase 3 data for HTX-011 demonstrated statistically significant reductions in pain intensity and opioid use through 72 hours post-surgery compared to placebo and the current standard of care, bupivacaine, Jackson writes. He notes that management believes the data support an opioid-sparing labeling claim for HTX-011. This would provide a significant competitive advantage, the analyst contends.
04/05/18
EVER
04/05/18
INITIATION
Target $56
EVER
Outperform
Heron Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Joshua Schimmer started Heron Therapeutics (HRTX) with an Outperform rating and $56 price target. He said that given the marked differentiation versus Pacira's (PCRX) Exparel, peak sales for Heron's HTX-011 could approach $2.5B, while Sustol/Cinvanti could add another $300M at peak. These estimates could drive a valuation potentially approaching $11B, or nearly $175 per share, in a bullish scenario, said Schimmer.

TODAY'S FREE FLY STORIES

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

FN

Fabrinet

$55.23

0.67 (1.23%)

17:25
02/15/19
02/15
17:25
02/15/19
17:25
Hot Stocks
Fabrinet CFO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

UBER

Uber

$0.00

(0.00%)

17:24
02/15/19
02/15
17:24
02/15/19
17:24
Periodicals
Uber sues NYC over move to cap number of ride-hailing drivers, Bloomberg says »

Uber is suing New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

17:19
02/15/19
02/15
17:19
02/15/19
17:19
Periodicals
House Democrats to probe POTUS emergency declaration, Bloomberg says »

The House Judiciary…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$51.71

0.25 (0.49%)

17:11
02/15/19
02/15
17:11
02/15/19
17:11
Hot Stocks
Oracle authorizes additional $12B stock buyback under existing program »

In a regulatory 8K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

SBLK

Star Bulk Carriers

$8.21

0.13 (1.61%)

17:03
02/15/19
02/15
17:03
02/15/19
17:03
Hot Stocks
Star Bulk Carriers acquires 95,605 of its common shares »

Star Bulk Carriers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLI

Hollysys

$20.56

0.26 (1.28%)

17:02
02/15/19
02/15
17:02
02/15/19
17:02
Earnings
Hollysys reports Q2 adjusted EPS 73c, consensus 59c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

AKS

AK Steel

$2.98

-0.015 (-0.50%)

16:58
02/15/19
02/15
16:58
02/15/19
16:58
Syndicate
Breaking Syndicate news story on AK Steel »

AK Steel files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
02/15/19
02/15
16:55
02/15/19
16:55
General news
Treasury Market Summary: i »

Treasury Market Summary:…

LPTX

Leap Therapeutics

$1.65

(0.00%)

16:53
02/15/19
02/15
16:53
02/15/19
16:53
Hot Stocks
Valence Helix Investments discloses 10.99% stake in Leap Therapeutics »

Valence Helix disclosed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$23.25

-0.24 (-1.02%)

16:52
02/15/19
02/15
16:52
02/15/19
16:52
Hot Stocks
Mid Penn Bancorp seeks approval to relocate Allentown Boulevard branch »

Mid Penn Bank, subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$423.79

8.54 (2.06%)

, AMGN

Amgen

$188.31

1.6 (0.86%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
Regeneron says EPO revokes Immunex's European patent No. 2,990,420 »

Regeneron…

REGN

Regeneron

$423.79

8.54 (2.06%)

AMGN

Amgen

$188.31

1.6 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 28

    Apr

  • 13

    May

UPS

UPS

$110.89

-0.91 (-0.81%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
UPS CFO sells 9.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DAL

Delta Air Lines

$51.09

0.58 (1.15%)

16:43
02/15/19
02/15
16:43
02/15/19
16:43
Syndicate
Breaking Syndicate news story on Delta Air Lines »

Delta Air Lines files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$110.89

-0.91 (-0.81%)

16:42
02/15/19
02/15
16:42
02/15/19
16:42
Hot Stocks
UPS raises quarterly dividend to 96c per share from 91c »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.